SV001
/ Shanghai Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
August 18, 2025
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
(clinicaltrials.gov)
- P2 | N=48 | Not yet recruiting | Sponsor: Shanghai Synvida Biotechnology Co.,Ltd.
New P2 trial • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
April 18, 2025
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
(clinicaltrials.gov)
- P1 | N=53 | Recruiting | Sponsor: Shanghai Synvida Biotechnology Co.,Ltd. | Trial completion date: Mar 2025 ➔ Dec 2025 | Trial primary completion date: Nov 2024 ➔ Nov 2025
Trial completion date • Trial primary completion date • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
February 20, 2024
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
(clinicaltrials.gov)
- P1 | N=53 | Recruiting | Sponsor: Shanghai Synvida Biotechnology Co.,Ltd.
New P1 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 3
Of
3
Go to page
1